Treatment time constraints and unmet medical needs in acute cerebral infarction
First written in FY2022-Q3. 6 of 7 entries say "Restated". Latest entry: FY2025.
1 other company's latest entry also says "Restated".
- FY2025RestatedAnnual report
「Thrombolytic therapy is limited to 4.5 hours after onset and mechanical thrombectomy to 8 hours, creating time constraints between onset and treatment and leaving the area with insufficient treatment effects.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2024RestatedAnnual report
「Thrombolytic therapy is limited to 4.5 hours after onset and mechanical thrombectomy to 8 hours, creating time constraints between onset and treatment and leaving the area with insufficient treatment effects.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2024-Q3RestatedAnnual report
「In the treatment of acute ischemic stroke, thrombolytic therapy, a reperfusion therapy, is limited to 4.5 hours after onset, while mechanical thrombectomy is limited to 8 hours after onset. This is an area in which sufficient treatment effects have not been achieved because of the time constraints between onset and treatment. Compared with conventional thrombolytic and mechanical thrombectomy therapies, treatment with Redasemtide offers a therapeutic option with less stringent time constraints and is expected to address these unmet medical needs.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2024-Q1RestatedAnnual report
「In the treatment of acute ischemic stroke, thrombolytic therapy, a reperfusion therapy, is limited to 4.5 hours after onset, while mechanical thrombectomy is limited to 8 hours after onset. This is an area in which sufficient treatment effects have not been achieved because of the time constraints between onset and treatment. Compared with conventional thrombolytic and mechanical thrombectomy therapies, treatment with Redasemtide offers a therapeutic option with less stringent time constraints and is expected to address these unmet medical needs.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2023-Q1RestatedAnnual report
「In the treatment of acute ischemic stroke, thrombolytic therapy, a reperfusion therapy, is limited to 4.5 hours after onset, while mechanical thrombectomy is limited to 8 hours after onset. This is an area in which sufficient treatment effects have not been achieved because of the time constraints between onset and treatment. Compared with conventional thrombolytic and mechanical thrombectomy therapies, treatment with Redasemtide offers a therapeutic option with less stringent time constraints and is expected to address these unmet medical needs.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2022RestatedAnnual report
「Thrombolytic therapy is limited to 4.5 hours after onset and mechanical thrombectomy to 8 hours, creating time constraints between onset and treatment and leaving the area with insufficient treatment effects.」
The time constraints of existing treatments for acute ischemic stroke and expectations for a treatment option using Redasemtide have been reaffirmed. - FY2022-Q3First statedAnnual report
「In the treatment of acute ischemic stroke, thrombolytic therapy, a reperfusion therapy, is limited to 4.5 hours after onset, while mechanical thrombectomy is limited to 8 hours after onset. This is an area in which sufficient treatment effects have not been achieved because of the time constraints between onset and treatment. Compared with conventional thrombolytic and mechanical thrombectomy therapies, treatment with Redasemtide offers a therapeutic option with less stringent time constraints and is expected to address these unmet medical needs.」
It was stated that, in acute ischemic stroke, existing thrombolytic therapy is subject to a time limit of 4.5 hours after onset and mechanical thrombectomy to a limit of 8 hours, leaving the area with insufficient treatment effects, and that expectations are high for Redasemtide.